Drug intelligence / Profile preview

ABO1022

Development stage: Unknown
Lead developer: Abogen Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ABO1022 is an mRNA-based vaccine candidate developed by Abogen for the prevention of tuberculosis (TB). The vaccine utilizes mRNA technology to encode multiple antigens derived from *Mycobacterium tuberculosis*, the causative agent of TB. By delivering these genetic instructions, ABO1022 is designed to stimulate both cellular and humoral immune responses against the pathogen. It represents a novel approach to TB vaccination, aiming to provide a more effective or durable alternative to the traditional BCG vaccine. The candidate is currently in clinical development, specifically in Phase 1/2 trials.

Other names: Abogen TB mRNA vaccine

Beyond the preview

Go deeper on ABO1022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABO1022.

Explore the full profile